Ethinyl Estradiol Therapy for Postmenopausal Women with Heavily Pre-Treated Endocrine-Responsive Metastatic Breast Cancer

Ethinyl estradiol(EE2)therapy has been reported to be an effective endocrine therapy for postmenopausal hormone receptor-positive advanced breast cancer, especially in the supposed acquired resistance state. The current study retrospectively investigated the efficacy and safety of EE2 therapy in pos...

Full description

Saved in:
Bibliographic Details
Published inGan to kagaku ryoho Vol. 46; no. 7; p. 1187
Main Authors Yukawa, Hiroko, Inoue, Hiroaki, Ogura, Kaoru, Sakaguchi, Shiho, Tanaka, Natsuko, Matsuoka, Aya, Kamimura, Mari, Hattori, Akinori, Kodera, Asaka, Naritaka, Yoshihiko, Hirano, Akira
Format Journal Article
LanguageJapanese
Published Japan 01.07.2019
Online AccessGet more information

Cover

More Information
Summary:Ethinyl estradiol(EE2)therapy has been reported to be an effective endocrine therapy for postmenopausal hormone receptor-positive advanced breast cancer, especially in the supposed acquired resistance state. The current study retrospectively investigated the efficacy and safety of EE2 therapy in postmenopausal women with hormone receptor-positive advanced breast cancer who had previously undergone multiple endocrine therapies. Twelve patients were enrolled; median lines of endocrine therapies were seven before EE2. Median PFS was 4.8 months and median overall survival was 10.0 months. Grade 3 adverse event comprised of anorexia in only one patient. EE2 therapy may be considered effective and safe in hormone receptor-positive advanced breast cancer even in late-stage endocrine therapy.
ISSN:0385-0684